Core Insights - DuPont de Nemours, Inc. has launched the Liveo Pharma TPE Ultra-Low Temp Tubing, designed for biopharmaceutical processing applications that require low-temperature resistance [1][2][3] Product Details - The new tubing is manufactured in an ISO Class 7 cleanroom, is sterilizable, weldable, and sealable, offering improved toughness and ductility [2] - It features resistance to bending, good pumpability, low spallation, and is phthalate-free, making it suitable for the biopharmaceutical industry [2] - This product is the second TPE tubing introduced by DuPont, complementing the existing Liveo Pharma TPE Tubing in their biopharma processing solutions [3] Financial Performance - DuPont's stock has decreased by 2.4% over the past year, while the industry has seen a decline of 18.8% [5] - The company anticipates full-year 2025 net sales to be between $12,800 million and $12,900 million, with operating EBITDA forecasted at $3,325 million to $3,375 million [6] Market Position - DuPont currently holds a Zacks Rank of 3 (Hold), with better-ranked stocks in the Basic Materials sector including Ingevity Corporation, Axalta Coating Systems, and Carpenter Technology Corporation [7] - Ingevity's current-year earnings estimate is $4.45 per share, while Axalta's is $2.51 per share, and Carpenter Technology's is $6.95 per share, with all showing positive earnings surprises in recent quarters [8][9]